[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-001", "question": "A 45-year-old man with a history of migraine presents with acute onset of right-sided hemiparesis and aphasia. MRI shows restricted diffusion in the left middle cerebral artery territory, but no large vessel occlusion on angiography. Lumbar puncture reveals normal opening pressure, 5 WBCs/μL (all lymphocytes), protein 45 mg/dL, glucose 60 mg/dL, and negative oligoclonal bands. Serum testing is positive for anti-NMDA receptor antibodies. What is the most appropriate next step in management?", "options": ["Initiate intravenous thrombolysis", "Administer high-dose intravenous methylprednisolone", "Start rituximab infusion", "Perform plasmapheresis", "Administer acyclovir empirically"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests anti-NMDA receptor encephalitis mimicking stroke, and rituximab is indicated for refractory cases or as first-line in severe presentations per subspecialty guidelines. High-dose steroids are often initial, but in antibody-positive cases with stroke-like features, rituximab targets B-cell depletion more effectively. Plasmapheresis is an alternative but not superior in this context without evidence of fulminant progression.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 45-year-old man with stroke-like presentation (hemiparesis, aphasia) and MRI-confirmed ischemia in MCA territory, but CSF shows mild lymphocytic pleocytosis and positive anti-NMDA receptor antibodies, suggesting autoimmune encephalitis. Key stem clues: acute stroke syndrome with restricted diffusion, no large vessel occlusion, positive anti-NMDA antibodies, mild CSF pleocytosis. The keyed answer (C: rituximab) assumes this is primarily anti-NMDA encephalitis with stroke-like features. However, the MRI explicitly shows restricted diffusion (acute ischemia), making this a true stroke with concurrent autoimmune findings. Standard anti-NMDA encephalitis treatment begins with first-line immunotherapy (steroids + IVIG or plasmapheresis), escalating to rituximab only if refractory. Option B (high-dose methylprednisolone) is equally or more defensible as initial immunotherapy. The rationale's claim that rituximab is 'first-line in severe presentations' contradicts standard guidelines where steroids/IVIG are first-line, with rituximab reserved for second-line. Options B and C are both defensible, creating ambiguity. Main medical issue: conflating stroke with autoimmune encephalitis presentation; rituximab is not standard first-line. Minimal fix: clarify whether this is refractory disease or specify prior first-line treatment failure to justify rituximab.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 45-year-old man with stroke-like presentation (hemiparesis, aphasia) and MRI-confirmed ischemia in MCA territory, but CSF shows mild lymphocytic pleocytosis and positive anti-NMDA receptor antibodies, suggesting autoimmune encephalitis. Key stem clues: acute stroke syndrome with restricted diffusion, no large vessel occlusion, positive anti-NMDA antibodies, mild CSF pleocytosis. The keyed answer (C: rituximab) assumes this is primarily anti-NMDA encephalitis with stroke-like features. However, the MRI explicitly shows restricted diffusion (acute ischemia), making this a true stroke with concurrent autoimmune findings. Standard anti-NMDA encephalitis treatment begins with first-line immunotherapy (steroids + IVIG or plasmapheresis), escalating to rituximab only if refractory. Option B (high-dose methylprednisolone) is equally or more defensible as initial immunotherapy. The rationale's claim that rituximab is 'first-line in severe presentations' contradicts standard guidelines where steroids/IVIG are first-line, with rituximab reserved for second-line. Options B and C are both defensible, creating ambiguity. Main medical issue: conflating stroke with autoimmune encephalitis presentation; rituximab is not standard first-line. Minimal fix: clarify whether this is refractory disease or specify prior first-line treatment failure to justify rituximab.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-002", "question": "A 62-year-old woman with Parkinson's disease on levodopa/carbidopa develops sudden visual hallucinations and paranoia. She has no fever, normal vital signs, and her Unified Parkinson's Disease Rating Scale score has worsened by 15 points. CSF analysis shows 10 WBCs/μL (mononuclear), protein 55 mg/dL, and negative PCR for herpes simplex virus. What is the most likely underlying mechanism?", "options": ["Dopaminergic overstimulation in mesolimbic pathways", "Alpha-synuclein aggregation in occipital lobes", "Autoimmune encephalitis with anti-LGI1 antibodies", "Lewy body deposition in limbic structures", "Serotonergic imbalance from medication withdrawal"], "answer": "C", "answer_index": 2, "explanation": "This scenario points to anti-LGI1 encephalitis, which can mimic psychiatric decompensation in Parkinson's patients and is associated with faciobrachial dystonic seizures or hallucinations. Dopaminergic effects are common but do not explain the CSF pleocytosis. Lewy body involvement is typical in dementia with Lewy bodies but lacks the acute inflammatory CSF findings here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer (C) is not the best answer. Key stem clues: 62-year-old woman with established Parkinson's disease on levodopa/carbidopa develops sudden visual hallucinations and paranoia with worsening UPDRS score. CSF shows mild pleocytosis (10 WBCs/μL mononuclear), mildly elevated protein (55 mg/dL), negative HSV PCR. The question asks for the \\\"most likely underlying mechanism.\\\" The keyed answer (anti-LGI1 encephalitis) is implausible as the primary mechanism. Anti-LGI1 encephalitis typically presents with faciobrachial dystonic seizures, hyponatremia, and more prominent inflammatory CSF changes; it would not be the \\\"most likely\\\" cause in a known PD patient on dopaminergic therapy developing hallucinations. Option A (dopaminergic overstimulation) is the most likely mechanism given the clinical context - visual hallucinations and paranoia are well-recognized complications of levodopa therapy in PD patients. The mild CSF pleocytosis (10 WBCs) can occur in PD itself or be incidental. Main logical issue: The key contradicts standard clinical reasoning - dopaminergic psychosis is far more common than autoimmune encephalitis in this scenario. Main medical accuracy issue: The rationale incorrectly dismisses dopaminergic effects despite them being the leading cause of psychosis in treated PD. Minimal fix: Change the correct answer key to A, or add more specific findings for anti-LGI1 encephalitis (hyponatremia, seizures, higher CSF pleocytosis).\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer (C) is not the best answer. Key stem clues: 62-year-old woman with established Parkinson's disease on levodopa/carbidopa develops sudden visual hallucinations and paranoia with worsening UPDRS score. CSF shows mild pleocytosis (10 WBCs/μL mononuclear), mildly elevated protein (55 mg/dL), negative HSV PCR. The question asks for the \"most likely underlying mechanism.\" The keyed answer (anti-LGI1 encephalitis) is implausible as the primary mechanism. Anti-LGI1 encephalitis typically presents with faciobrachial dystonic seizures, hyponatremia, and more prominent inflammatory CSF changes; it would not be the \"most likely\" cause in a known PD patient on dopaminergic therapy developing hallucinations. Option A (dopaminergic overstimulation) is the most likely mechanism given the clinical context - visual hallucinations and paranoia are well-recognized complications of levodopa therapy in PD patients. The mild CSF pleocytosis (10 WBCs) can occur in PD itself or be incidental. Main logical issue: The key contradicts standard clinical reasoning - dopaminergic psychosis is far more common than autoimmune encephalitis in this scenario. Main medical accuracy issue: The rationale incorrectly dismisses dopaminergic effects despite them being the leading cause of psychosis in treated PD. Minimal fix: Change the correct answer key to A, or add more specific findings for anti-LGI1 encephalitis (hyponatremia, seizures, higher CSF pleocytosis).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-003", "question": "A 28-year-old woman at 32 weeks gestation presents with severe pelvic pain and vaginal bleeding. Ultrasound shows a low-lying placenta with abnormal lacunae and loss of the retroplacental clear space. MRI confirms myometrial thinning and turbulent flow voids. What is the most appropriate management strategy?", "options": ["Expectant management with bed rest", "Immediate cesarean delivery", "Uterine artery embolization", "Balloon tamponade post-delivery", "Prophylactic internal iliac artery ligation"], "answer": "E", "answer_index": 4, "explanation": "This describes placenta accreta spectrum, and prophylactic internal iliac artery ligation reduces hemorrhage risk during planned cesarean hysterectomy in high-risk cases. Immediate delivery risks uncontrolled bleeding without preparation. Embolization is adjunctive but not primary in antenatal planning for accreta.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The vignette describes placenta accreta spectrum (PAS) at 32 weeks with imaging findings (lacunae, loss of retroplacental space, myometrial thinning, turbulent flow). Key stem clues: 32 weeks gestation (preterm), severe symptoms (pain/bleeding), confirmed PAS on ultrasound and MRI. The clinical problem is managing diagnosed PAS with active bleeding at preterm gestation. Option E (prophylactic internal iliac artery ligation) is an intraoperative adjunct during planned cesarean hysterectomy, not a management strategy for a patient presenting acutely at 32 weeks. Option B (immediate cesarean delivery) is most appropriate given active bleeding and severe symptoms requiring delivery, with multidisciplinary surgical preparation. The rationale conflates antenatal planning (which would involve scheduled delivery at 34-36 weeks with surgical preparation) with acute management of symptomatic presentation. Main logical issue: The keyed answer represents an intraoperative technique rather than the overall management strategy for acute presentation. Main medical accuracy issue: Internal iliac artery ligation is controversial, not standard prophylaxis, and has limited efficacy in PAS. Minimal fix: Change key to B or reframe question as 'What intraoperative adjunct may be considered?' to make E defensible.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The vignette describes placenta accreta spectrum (PAS) at 32 weeks with imaging findings (lacunae, loss of retroplacental space, myometrial thinning, turbulent flow). Key stem clues: 32 weeks gestation (preterm), severe symptoms (pain/bleeding), confirmed PAS on ultrasound and MRI. The clinical problem is managing diagnosed PAS with active bleeding at preterm gestation. Option E (prophylactic internal iliac artery ligation) is an intraoperative adjunct during planned cesarean hysterectomy, not a management strategy for a patient presenting acutely at 32 weeks. Option B (immediate cesarean delivery) is most appropriate given active bleeding and severe symptoms requiring delivery, with multidisciplinary surgical preparation. The rationale conflates antenatal planning (which would involve scheduled delivery at 34-36 weeks with surgical preparation) with acute management of symptomatic presentation. Main logical issue: The keyed answer represents an intraoperative technique rather than the overall management strategy for acute presentation. Main medical accuracy issue: Internal iliac artery ligation is controversial, not standard prophylaxis, and has limited efficacy in PAS. Minimal fix: Change key to B or reframe question as 'What intraoperative adjunct may be considered?' to make E defensible.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-004", "question": "A 35-year-old woman with endometriosis undergoes laparoscopic excision and develops postoperative fever, leukocytosis, and pelvic pain. CT shows a 5 cm complex adnexal mass with gas bubbles. Blood cultures are negative, but vaginal cultures grow mixed anaerobes. What is the most likely diagnosis?", "options": ["Ovarian abscess from bowel perforation", "Endometrioma superinfection", "Tubo-ovarian abscess from pelvic inflammatory disease", "Postoperative hematoma with secondary infection", "Clostridial myonecrosis of the uterus"], "answer": "A", "answer_index": 0, "explanation": "Bowel perforation during endometriosis surgery can lead to ovarian abscess with gas-forming anaerobes, explaining the imaging and cultures. Endometrioma infection is less likely without prior instrumentation. Tubo-ovarian abscess typically involves gonadal pathogens, not mixed anaerobes from bowel flora.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. Key stem clues: postoperative fever/leukocytosis/pelvic pain after laparoscopic endometriosis excision; 5 cm complex adnexal mass with gas bubbles on CT; negative blood cultures; vaginal cultures with mixed anaerobes. The question asks for the most likely diagnosis. Option D (postoperative hematoma with secondary infection) best explains the clinical scenario: hematomas are common postoperative complications, and secondary infection with mixed anaerobes from vaginal flora accounts for the gas bubbles and positive vaginal cultures. Option A (ovarian abscess from bowel perforation) is keyed as correct but is problematic: bowel perforation is a serious complication that would typically present earlier with peritoneal signs, positive blood cultures, and free air/fluid on CT, not just an isolated adnexal mass. The rationale's claim that bowel perforation explains the findings is medically questionable. Option B is unlikely without prior endometrioma. Option C doesn't fit the postoperative timing or mixed anaerobes from bowel flora. Option E is extremely rare and doesn't match the presentation. Minimal fix: Change key to D, or add explicit stem details indicating bowel injury was recognized intraoperatively to justify A.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. Key stem clues: postoperative fever/leukocytosis/pelvic pain after laparoscopic endometriosis excision; 5 cm complex adnexal mass with gas bubbles on CT; negative blood cultures; vaginal cultures with mixed anaerobes. The question asks for the most likely diagnosis. Option D (postoperative hematoma with secondary infection) best explains the clinical scenario: hematomas are common postoperative complications, and secondary infection with mixed anaerobes from vaginal flora accounts for the gas bubbles and positive vaginal cultures. Option A (ovarian abscess from bowel perforation) is keyed as correct but is problematic: bowel perforation is a serious complication that would typically present earlier with peritoneal signs, positive blood cultures, and free air/fluid on CT, not just an isolated adnexal mass. The rationale's claim that bowel perforation explains the findings is medically questionable. Option B is unlikely without prior endometrioma. Option C doesn't fit the postoperative timing or mixed anaerobes from bowel flora. Option E is extremely rare and doesn't match the presentation. Minimal fix: Change key to D, or add explicit stem details indicating bowel injury was recognized intraoperatively to justify A.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-005", "question": "A 58-year-old man with hypertrophic cardiomyopathy presents with syncope. Echocardiogram shows left ventricular outflow tract gradient of 80 mmHg at rest, increasing to 120 mmHg with Valsalva. He is on beta-blockers but remains symptomatic. Genetic testing reveals a MYH7 mutation. What is the most appropriate next intervention?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantable cardioverter-defibrillator placement", "Dual-chamber pacing", "Mavacamten therapy"], "answer": "E", "answer_index": 4, "explanation": "Mavacamten, a cardiac myosin inhibitor, is indicated for symptomatic obstructive hypertrophic cardiomyopathy refractory to beta-blockers, targeting the underlying MYH7-related hypercontractility. Alcohol ablation and myectomy are invasive options for severe cases, but mavacamten offers medical management first. ICD is for arrhythmia risk, not outflow obstruction.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 58-year-old man with obstructive HCM (LVOT gradient 80 mmHg at rest, 120 mmHg with Valsalva), syncope despite beta-blockers, and MYH7 mutation. Key discriminating findings: severe obstruction (gradient >50 mmHg), refractory symptoms on medical therapy, syncope (high-risk feature). The question asks for \\\"most appropriate next intervention.\\\" The keyed answer (E, mavacamten) represents newer medical therapy for obstructive HCM. However, option C (ICD) is equally defensible: syncope in HCM is a major sudden cardiac death risk factor requiring ICD per guidelines (2020 AHA/ACC), independent of obstruction management. The stem conflates two parallel management tracks: (1) obstruction relief and (2) SCD prevention. Both mavacamten (for obstruction) and ICD (for syncope/SCD risk) are appropriate \\\"next\\\" interventions. The rationale dismisses ICD as \\\"for arrhythmia risk, not outflow obstruction,\\\" but syncope IS an arrhythmia/SCD concern requiring ICD. Medical accuracy: Mavacamten is FDA-approved for symptomatic obstructive HCM, but ICD takes precedence when high-risk features (syncope) are present. Minimal fix: Specify \\\"next intervention to reduce outflow obstruction\\\" to exclude ICD, or remove syncope to eliminate SCD risk consideration.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 58-year-old man with obstructive HCM (LVOT gradient 80 mmHg at rest, 120 mmHg with Valsalva), syncope despite beta-blockers, and MYH7 mutation. Key discriminating findings: severe obstruction (gradient >50 mmHg), refractory symptoms on medical therapy, syncope (high-risk feature). The question asks for \"most appropriate next intervention.\" The keyed answer (E, mavacamten) represents newer medical therapy for obstructive HCM. However, option C (ICD) is equally defensible: syncope in HCM is a major sudden cardiac death risk factor requiring ICD per guidelines (2020 AHA/ACC), independent of obstruction management. The stem conflates two parallel management tracks: (1) obstruction relief and (2) SCD prevention. Both mavacamten (for obstruction) and ICD (for syncope/SCD risk) are appropriate \"next\" interventions. The rationale dismisses ICD as \"for arrhythmia risk, not outflow obstruction,\" but syncope IS an arrhythmia/SCD concern requiring ICD. Medical accuracy: Mavacamten is FDA-approved for symptomatic obstructive HCM, but ICD takes precedence when high-risk features (syncope) are present. Minimal fix: Specify \"next intervention to reduce outflow obstruction\" to exclude ICD, or remove syncope to eliminate SCD risk consideration.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-006", "question": "A 70-year-old woman with atrial fibrillation on apixaban develops acute chest pain. Coronary angiography shows spontaneous coronary artery dissection in the left anterior descending artery. She is hemodynamically stable with TIMI 3 flow. What is the most appropriate management?", "options": ["Percutaneous coronary intervention with stenting", "Continuation of apixaban with close monitoring", "Switch to dual antiplatelet therapy", "Surgical bypass grafting", "Conservative management with beta-blockers"], "answer": "E", "answer_index": 4, "explanation": "Conservative management with beta-blockers is preferred for stable spontaneous coronary artery dissection with preserved flow, as it promotes healing and reduces shear stress. Anticoagulation like apixaban increases bleeding risk in dissection. PCI is reserved for unstable cases due to high complication rates.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - option B is the most defensible best answer. Key stem clues: 70-year-old woman with atrial fibrillation on apixaban (chronic anticoagulation indication), hemodynamically stable SCAD with TIMI 3 flow (preserved perfusion). The clinical problem is managing stable SCAD in a patient requiring chronic anticoagulation for AF. For stable SCAD with TIMI 3 flow, conservative management is standard. However, the patient has atrial fibrillation requiring anticoagulation - this cannot simply be discontinued. The keyed answer (E: beta-blockers alone) fails to address the ongoing AF anticoagulation need, which carries stroke risk if stopped. Option B (continue apixaban with monitoring) appropriately balances both conditions: conservative SCAD management while maintaining necessary AF anticoagulation. While anticoagulation theoretically increases dissection bleeding risk, abruptly stopping apixaban in AF creates immediate thromboembolic risk. Current evidence supports cautious continuation of anticoagulation in stable SCAD when indicated for other conditions. Option C (DAPT) would require stopping apixaban, increasing stroke risk. Options A and D are inappropriate for stable SCAD. Main logical issue: The item fails to recognize that AF anticoagulation cannot be abandoned. Minimal fix: Remove AF/apixaban from stem, or change key to B with rationale acknowledging dual management needs.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - option B is the most defensible best answer. Key stem clues: 70-year-old woman with atrial fibrillation on apixaban (chronic anticoagulation indication), hemodynamically stable SCAD with TIMI 3 flow (preserved perfusion). The clinical problem is managing stable SCAD in a patient requiring chronic anticoagulation for AF. For stable SCAD with TIMI 3 flow, conservative management is standard. However, the patient has atrial fibrillation requiring anticoagulation - this cannot simply be discontinued. The keyed answer (E: beta-blockers alone) fails to address the ongoing AF anticoagulation need, which carries stroke risk if stopped. Option B (continue apixaban with monitoring) appropriately balances both conditions: conservative SCAD management while maintaining necessary AF anticoagulation. While anticoagulation theoretically increases dissection bleeding risk, abruptly stopping apixaban in AF creates immediate thromboembolic risk. Current evidence supports cautious continuation of anticoagulation in stable SCAD when indicated for other conditions. Option C (DAPT) would require stopping apixaban, increasing stroke risk. Options A and D are inappropriate for stable SCAD. Main logical issue: The item fails to recognize that AF anticoagulation cannot be abandoned. Minimal fix: Remove AF/apixaban from stem, or change key to B with rationale acknowledging dual management needs.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-007", "question": "A 40-year-old man returning from West Africa presents with fever, myalgias, and petechial rash. Labs show thrombocytopenia, elevated liver enzymes, and PCR positive for Lassa virus. He develops acute kidney injury with oliguria. What is the most appropriate therapeutic intervention?", "options": ["Intravenous ribavirin", "Supportive care with hemodialysis", "Convalescent plasma transfusion", "Favipiravir administration", "Monoclonal antibody therapy"], "answer": "A", "answer_index": 0, "explanation": "Intravenous ribavirin is the mainstay for Lassa fever, reducing mortality especially when initiated early, and it addresses viremia in cases with renal involvement. Supportive care is essential but not sufficient alone. Favipiravir is investigational and not standard for Lassa.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a classic Lassa fever presentation: travel to endemic West Africa, fever, myalgias, petechial rash, thrombocytopenia, elevated transaminases, and PCR confirmation. The acute kidney injury with oliguria represents severe disease. Key discriminating findings are PCR-confirmed Lassa virus with multi-organ involvement (hepatic and renal). Intravenous ribavirin (option A) is the established antiviral therapy for Lassa fever, with evidence showing mortality reduction when started early, particularly in severe cases. This is consistent with WHO and CDC guidance. Option B (supportive care with hemodialysis) addresses the renal complication but lacks specific antiviral therapy—supportive care alone is insufficient when specific treatment exists. Option C (convalescent plasma) lacks robust evidence for Lassa fever. Option D (favipiravir) remains investigational without established efficacy data. Option E (monoclonal antibody) is not standard therapy for Lassa fever. The keyed answer is medically accurate and uniquely defensible as best practice. No logical flaws exist; the stem provides sufficient detail for diagnosis and treatment selection. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic Lassa fever presentation: travel to endemic West Africa, fever, myalgias, petechial rash, thrombocytopenia, elevated transaminases, and PCR confirmation. The acute kidney injury with oliguria represents severe disease. Key discriminating findings are PCR-confirmed Lassa virus with multi-organ involvement (hepatic and renal). Intravenous ribavirin (option A) is the established antiviral therapy for Lassa fever, with evidence showing mortality reduction when started early, particularly in severe cases. This is consistent with WHO and CDC guidance. Option B (supportive care with hemodialysis) addresses the renal complication but lacks specific antiviral therapy—supportive care alone is insufficient when specific treatment exists. Option C (convalescent plasma) lacks robust evidence for Lassa fever. Option D (favipiravir) remains investigational without established efficacy data. Option E (monoclonal antibody) is not standard therapy for Lassa fever. The keyed answer is medically accurate and uniquely defensible as best practice. No logical flaws exist; the stem provides sufficient detail for diagnosis and treatment selection. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-008", "question": "A 55-year-old immunocompromised patient with lung transplant develops dyspnea and ground-glass opacities on CT. Bronchoalveolar lavage PCR is positive for Pneumocystis jirovecii, but serum beta-D-glucan is negative. He is on trimethoprim-sulfamethoxazole prophylaxis. What explains the breakthrough infection?", "options": ["Dihydropteroate synthase gene mutation", "Non-adherence to prophylaxis", "Concurrent cytomegalovirus co-infection", "Inadequate dosing in obesity", "Atovaquone cross-resistance"], "answer": "A", "answer_index": 0, "explanation": "Mutations in the dihydropteroate synthase gene confer resistance to sulfamethoxazole in Pneumocystis, leading to breakthrough despite prophylaxis in immunocompromised hosts. Non-adherence is common but less likely with negative beta-D-glucan suggesting low burden. CMV co-infection exacerbates but does not cause resistance.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a lung-transplant recipient on TMP-SMX prophylaxis who develops proven PJP (PCR-positive), asking for the mechanism of breakthrough infection. Key discriminating findings: (1) confirmed PJP despite appropriate prophylaxis, (2) immunocompromised host, (3) negative beta-D-glucan (may reflect low organism burden or test limitation). Option A (dihydropteroate synthase mutation) is the established mechanism of sulfa resistance in Pneumocystis and directly explains breakthrough on TMP-SMX. Option B (non-adherence) is plausible but the stem states \\\"He is on\\\" prophylaxis, implying adherence; non-adherence would be a clinical assumption not supported by the vignette. Option C (CMV co-infection) can worsen immunosuppression but does not confer drug resistance. Option D (inadequate dosing in obesity) is not mentioned and requires inventing a fact. Option E (atovaquone cross-resistance) is not relevant since the patient is on TMP-SMX, not atovaquone. The item is logically valid with a unique best answer matching the key. Medical accuracy: dihydropteroate synthase mutations are well-documented in TMP-SMX-resistant PJP. Minor issue: negative beta-D-glucan in proven PJP is unusual (sensitivity ~90%) but can occur; this does not undermine the core teaching point. Minimal fix: none required; item is defensible as written.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a lung-transplant recipient on TMP-SMX prophylaxis who develops proven PJP (PCR-positive), asking for the mechanism of breakthrough infection. Key discriminating findings: (1) confirmed PJP despite appropriate prophylaxis, (2) immunocompromised host, (3) negative beta-D-glucan (may reflect low organism burden or test limitation). Option A (dihydropteroate synthase mutation) is the established mechanism of sulfa resistance in Pneumocystis and directly explains breakthrough on TMP-SMX. Option B (non-adherence) is plausible but the stem states \"He is on\" prophylaxis, implying adherence; non-adherence would be a clinical assumption not supported by the vignette. Option C (CMV co-infection) can worsen immunosuppression but does not confer drug resistance. Option D (inadequate dosing in obesity) is not mentioned and requires inventing a fact. Option E (atovaquone cross-resistance) is not relevant since the patient is on TMP-SMX, not atovaquone. The item is logically valid with a unique best answer matching the key. Medical accuracy: dihydropteroate synthase mutations are well-documented in TMP-SMX-resistant PJP. Minor issue: negative beta-D-glucan in proven PJP is unusual (sensitivity ~90%) but can occur; this does not undermine the core teaching point. Minimal fix: none required; item is defensible as written.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-009", "question": "A 50-year-old woman with rheumatoid arthritis on tofacitinib presents with symmetric polyarthritis flare, fever, and macular rash. Labs show pancytopenia, ferritin 10,000 ng/mL, triglycerides 400 mg/dL, and fibrinogen 100 mg/dL. Bone marrow biopsy reveals hemophagocytosis. What is the most appropriate initial treatment?", "options": ["High-dose glucocorticoids", "Cyclosporine A", "Anakinra", "Etoposide-based chemotherapy", "Intravenous immunoglobulin"], "answer": "C", "answer_index": 2, "explanation": "Anakinra, an IL-1 inhibitor, is effective for macrophage activation syndrome in rheumatoid arthritis, targeting cytokine storm and improving survival without broad immunosuppression. Glucocorticoids are adjunctive but insufficient alone in JAK inhibitor-associated cases. Etoposide is for refractory HLH but not first-line here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (HLH) in a patient on tofacitinib (JAK inhibitor) with classic features: fever, cytopenias, hyperferritinemia (>10,000), hypertriglyceridemia, hypofibrinogenemia, and hemophagocytosis. Key stem clues support MAS/HLH diagnosis. The keyed answer (C, anakinra) is defensible based on emerging evidence for IL-1 blockade in MAS, particularly in rheumatologic contexts. However, option A (high-dose glucocorticoids) is equally defensible as initial therapy. Standard HLH-2004 protocol and most guidelines recommend high-dose corticosteroids as first-line treatment for secondary HLH/MAS, often combined with other agents. While anakinra shows promise in refractory or steroid-resistant cases, glucocorticoids remain the established initial approach in most protocols. The rationale dismisses glucocorticoids as 'adjunctive but insufficient alone,' but this contradicts standard practice where they are primary initial therapy. Medical accuracy issue: The item implies anakinra is preferred over glucocorticoids for initial treatment, which is not consensus. Both are defensible, creating ambiguity. Minimal fix: Specify 'steroid-refractory' MAS or add contraindication to glucocorticoids to make anakinra uniquely best.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (HLH) in a patient on tofacitinib (JAK inhibitor) with classic features: fever, cytopenias, hyperferritinemia (>10,000), hypertriglyceridemia, hypofibrinogenemia, and hemophagocytosis. Key stem clues support MAS/HLH diagnosis. The keyed answer (C, anakinra) is defensible based on emerging evidence for IL-1 blockade in MAS, particularly in rheumatologic contexts. However, option A (high-dose glucocorticoids) is equally defensible as initial therapy. Standard HLH-2004 protocol and most guidelines recommend high-dose corticosteroids as first-line treatment for secondary HLH/MAS, often combined with other agents. While anakinra shows promise in refractory or steroid-resistant cases, glucocorticoids remain the established initial approach in most protocols. The rationale dismisses glucocorticoids as 'adjunctive but insufficient alone,' but this contradicts standard practice where they are primary initial therapy. Medical accuracy issue: The item implies anakinra is preferred over glucocorticoids for initial treatment, which is not consensus. Both are defensible, creating ambiguity. Minimal fix: Specify 'steroid-refractory' MAS or add contraindication to glucocorticoids to make anakinra uniquely best.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-010", "question": "A 65-year-old man with giant cell arteritis on prednisone taper develops jaw claudication and vision loss. ESR is 80 mm/hr, and temporal artery biopsy is negative. CTA shows aortic arch involvement. What is the most appropriate escalation in therapy?", "options": ["Increase prednisone to 60 mg daily", "Add methotrexate", "Initiate tocilizumab", "Start cyclophosphamide", "Perform temporal artery ultrasound"], "answer": "C", "answer_index": 2, "explanation": "Tocilizumab, an IL-6 inhibitor, is indicated for refractory giant cell arteritis with large vessel involvement, reducing relapse and steroid requirements. High-dose prednisone is initial but inadequate for escalation in biopsy-negative cases. Methotrexate is steroid-sparing but less effective for vision-threatening disease.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 65-year-old man with established GCA on prednisone taper who develops refractory disease (jaw claudication, vision loss) with elevated ESR, negative temporal artery biopsy, and CTA-confirmed large-vessel involvement. Key discriminating findings: (1) refractory/relapsing GCA despite prednisone, (2) vision-threatening manifestations, (3) large-vessel (aortic arch) involvement, (4) negative biopsy (not uncommon in large-vessel GCA). The question asks for therapy escalation. Tocilizumab (C) is the evidence-based choice: FDA-approved for GCA, particularly effective in large-vessel disease, steroid-sparing, and appropriate for refractory cases with vision threat. Option A (increase prednisone) is inadequate escalation for refractory disease already failing steroids. Option B (methotrexate) is steroid-sparing but insufficient for vision-threatening refractory disease. Option D (cyclophosphamide) is not standard GCA therapy. Option E (ultrasound) is diagnostic, not therapeutic escalation. The keyed answer aligns with current ACR/EULAR guidelines and GiACTA trial evidence supporting tocilizumab for refractory GCA. No logical flaws or medical inaccuracies. Minimal fix: none needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 65-year-old man with established GCA on prednisone taper who develops refractory disease (jaw claudication, vision loss) with elevated ESR, negative temporal artery biopsy, and CTA-confirmed large-vessel involvement. Key discriminating findings: (1) refractory/relapsing GCA despite prednisone, (2) vision-threatening manifestations, (3) large-vessel (aortic arch) involvement, (4) negative biopsy (not uncommon in large-vessel GCA). The question asks for therapy escalation. Tocilizumab (C) is the evidence-based choice: FDA-approved for GCA, particularly effective in large-vessel disease, steroid-sparing, and appropriate for refractory cases with vision threat. Option A (increase prednisone) is inadequate escalation for refractory disease already failing steroids. Option B (methotrexate) is steroid-sparing but insufficient for vision-threatening refractory disease. Option D (cyclophosphamide) is not standard GCA therapy. Option E (ultrasound) is diagnostic, not therapeutic escalation. The keyed answer aligns with current ACR/EULAR guidelines and GiACTA trial evidence supporting tocilizumab for refractory GCA. No logical flaws or medical inaccuracies. Minimal fix: none needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]